Karyopharm collects $20M in first funding round

November 4, 2010

Stealthy pharmaceutical startup Karyopharm Therapeutics Inc., born out of the ashes of Epix Pharmaceuticals, has raised a $20 million Series A financing round from unnamed backers, officials said.

The Newton-based company is focusing on the new field of nuclear transport modulators, a broad-reaching mechanism that regulates many of the molecules associated with many diseases in both humans and animals. Specifically, they are looking to stop the mechanism that allows nucleus material to be exported out of a diseased cell, which happens when viruses replicate, or tumors grow. Keeping the diseased cell from exporting its nuclear material will cause it to die, without affecting nearby healthy cells, officials said.

Karyopharm co-founder and acting president Sharon Shacham was senior vice president of drug development at Epix from 2000 until April of 2009, the same month then-bankrupt Epix announced the sale of the U.S., Australian and Canadian rights of its vascular imaging agent Vasovist to Lantheus Medical Imaging Inc. for $28 million to help clear up debt owed to partner Bayer Schering Pharma.  In July, Epix announced it had to liquidate all assets.

Also serving as a board member and clinical advisor at Karyopharm is Michael Kauffman, former CEO at Epix. The other co-founder of Karyopharm is Harvard Medical School professor and director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute, Ronald DePinho, one of the founders of Aveo Pharmaceuticals Inc. of Cambridge.

Karyopharm was founded in 2009 by Shacham, DePinho, Kauffman and DePinho’s fellow Belfer Institute researcher Giulio Draetta.

 

Article from MassHighTech: http://www.masshightech.com/stories/2010/11/01/daily26-Karyopharm-collects-20M-in-first-funding-round.html

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.